Search Results for: THERAPEUTIC FOCUS Targeted Payload Therapies
Articles
ANTIBODY DRUG CONJUGATES – ADC Development Using SMARTag(TM) Technology April 1, 2014
Robyn M. Barfield, PhD, and David Rabuka, PhD, say that despite challenges, there has been progress in advancing complex compounds through clinical trials and successfully treating patients, and these bioconjugate compounds include a subset of molecules known as ADCs.
BIOAVAILABILITY ENHANCEMENT – Navigating a Broad Spectrum of Solubilization Technologies: Part II of III October 15, 2013
Marshall Crew, PhD, President & CEO, Agere Pharmaceuticals, Inc., continues his multiple-part series discussing today’s most challenging issues in solubility.
PLATFORM TECHNOLOGY – Tumor-Targeting Platform Delivers the Next Generation of Pediatric Cancer Drugs December 31, 2012
Contributor Cindy H. Dubin examines the desperate need for therapies that can address underserved populations, eradicate the cancer state without severe complications, and prolong the lifespan of the patient after diagnosis, and how NanoSmart Pharmaceuticals, with its unique tumor-targeting platform, has taken on that challenge.